A disease-modifying therapy for stage 3 T1D, a second once-weekly insulin, and automated insulin delivery for T2D mark a busy year in diabetes care.
Publication|Articles|August 23, 2023
- August 2023
- Volume 89
- Issue 8
August 2023 Pet Peeves
Advertisement
Too Late
Patients who tell the pharmacist about a discount card after they’ve already paid.
Articles in this issue
about 3 years ago
Fun Facts: August 2023about 3 years ago
Zero in on Professionalism When Strengthening Communication Skillsabout 3 years ago
Interactive Case Studies: August 2023about 3 years ago
Opioid Safety Is a Vital Part of Medication Therapy Managementabout 3 years ago
The Medicine Shoppe Emphasizes Personalized Careabout 3 years ago
Dry Eye Reliefabout 3 years ago
Zydus Pharmaceuticals (USA) Inc. Profileabout 3 years ago
August 2023: Skin Health Watchabout 3 years ago
August Generic Product NewsAdvertisement
Related to this article
October’s pain management coverage examined postoperative suzetrigine, pharmacist follow-up for cancer-related neuropathic pain, constipation prevention, and counseling patients concerned about prescribed opioids.
CDC surveillance data show that approximately 10% of adults hospitalized with RSV died during hospitalization or within 60 days of discharge.
VAX-31 met all primary immunogenicity end points against PCV20 and PCV21 in the pivotal OPUS-1 trial.
Young adults who vaped daily but never smoked had lower flow-mediated dilation and peak oxygen uptake than peers who used neither product.
Expert Q&A: Geisinger Investigator Discusses Low Flu Vaccination Rates, ICU Findings in Older Adults
A study author explains how pharmacists can help close vaccination gaps in rural communities and what lower ICU admission rates among vaccinated older adults may mean.
From AKI dosing to CKM therapeutic inertia, experts at ASN Kidney Week 2026 pointed to pharmacists as key to moving new kidney data into practice.
Kidney Week 2026 posters show low-density lipoprotein cholesterol (LDL-C) fell by half in patients receiving dialysis, and oral enlicitide needed no dose adjustment for renal impairment.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Diabetes Awareness Month Opens Amid New T1D, T2D Approvals
2
October 2026 in Pain Management: 4 Updates on Treatment and Pharmacy Practice
3
What Happens Before the First Dose? 5 Steps That Shape Lung Cancer Treatment
4
COVID-19 ‘Is Not Done With Us’: Pharmacist Urges Continued Vaccination Ahead of Seasonal Peaks
5